Black Friday Savings ! Exclusive Deals on Latest Pharma and Medical Technology Reports.

Explore Now

Neurotrophic Keratopathy Epidemiology Forecast

DelveInsight’s ‘Neurotrophic keratopathy (NK)—Epidemiology Forecast–2030’ report delivers an in-depth understanding of the NK, historical and forecasted epidemiology as well as the NK trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018–2030

Neurotrophic keratopathy (NK) Disease Understanding

The eye in humans is one of the vital sensory organs that help in seeing around. The cornea is one of the exposed parts of the human eye that can be affected by different ophthalmic conditions if not taken proper care of it.

 

One such ophthalmic disorder affecting the cornea is neurotrophic keratopathy (NK), also called neurotrophic keratitis. It is a rare, degenerative ophthalmic disorder characterized by a reduction or absence of corneal sensitivity.

 

Corneal sensitivity is controlled by the trigeminal nerve (fifth cranial nerve). Corneal nerves also provide trophic (nutritive) support and play a key role in maintaining anatomical integrity and function of the cornea, particularly of epithelium. The cornea is one of the most richly innervated parts of the body. Corneal innervation provides sensations and is important in the maintenance of the structure and function of the cornea. Normal innervation helps regulate epithelial integrity, proliferation, and wound healing of the cornea.

 

Damage to trigeminal innervation is seen as the primary cause behind NK. It can be considered as the hallmark of the condition. Corneal nerves play an essential role in tear production and preservation of the normal metabolism and function of the ocular surface. Loss of sensitivity impairs corneal wound healing, leading to epithelial changes, including punctate epithelial keratopathy, persistent epithelial defects (PEDs), and corneal ulcer. A wide range of ocular and systemic conditions, including herpetic keratitis, ocular chemical burns, corneal surgery, diabetes, multiple sclerosis, and neurosurgical procedures, can cause NK by damaging trigeminal innervation.

Continued in the report…..

Neurotrophic keratopathy (NK) Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Cases of Neurotrophic keratopathy, Total Diagnosed Prevalent Cases of Neurotrophic keratopathy, Gender-specific Diagnosed Prevalent Cases of Neurotrophic keratopathy, and Stage-specific Diagnosed Prevalent Cases of Neurotrophic keratopathy scenario in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2018 to 2030.

Neurotrophic keratopathy (NK) Detailed Epidemiology Segmentation

  • In 2020, the total prevalent cases of Neurotrophic Keratopathy (NK) were found out to be 136,945 in the 7MM, these cases are expected to grow during the study period 2018–2030.
  • The highest number, 65,000 cases of NK were prevalent in the US in 2020 and the least number, 7,965 cases of NK were prevalent in 2020, in Spain.
  • The estimates suggest the highest diagnosed prevalent cases of NK was found in the United States with 49,999 cases in 2020.
  • As per DelveInsight’s analysis, a higher percentage of diagnosed prevalence was observed for females than males among all the 7MM countries.
  • Among the EU-5 countries, the United Kingdom had the highest diagnosed prevalence of NK with 12,826 cases, followed by Germany (9,193 cases) and France (7,777 cases). On the other hand, Spain had the lowest diagnosed prevalent population of 5,718 cases in 2020.
  • Japan had 8,343 diagnosed prevalent cases of NK in 2020. Which is estimated to plummet down by 2030.

Scope of the Report

  • The report covers the descriptive overview of NK, explaining its causes, symptoms, pathophysiology, and other aspects.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of Neurotrophic keratopathy (NK).
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
  • The report provides the segmentation of the disease epidemiology for 7MM by Total Prevalent Cases of Neurotrophic keratopathy, Total Diagnosed Prevalent Cases of Neurotrophic keratopathy, Gender-specific Diagnosed Prevalent Cases of Neurotrophic keratopathy, and Stage-specific Diagnosed Prevalent Cases of Neurotrophic keratopathy.

Report Highlights

  • 10-Year Forecast of NK
  • 7MM Coverage
  • Total Prevalent Cases of Neurotrophic keratopathy
  • Total Diagnosed Prevalent Cases of Neurotrophic keratopathy
  • Gender-specific Diagnosed Prevalent Cases of Neurotrophic keratopathy,
  • Stage-specific Diagnosed Prevalent Cases of Neurotrophic keratopathy

Key Questions Answered

  • What are the disease risk, and burden of NK?
  • What is the historical NK patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient pool of NK at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to NK?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of NK during the forecast period (2021–2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2021–2030)?

Reasons to buy

The Neurotrophic keratopathy (NK) report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the 7MM NK epidemiology forecast.
  • The NK epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
  • The NK epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights

2. Report Introduction

4. Future Prospects

5. Executive Summary of Neurotrophic keratopathy (NK)

6. Key Events

7. Neurotrophic Keratopathy: Disease Background and Overview

7.1. Introduction

7.2. Signs and Symptoms

7.3. Stages and Clinical presentation of Neurotrophic keratitis

7.4. Causes

7.5. Pathogenesis

7.6. Diagnosis

7.6.1. Diagnostic Algorithm

7.6.2. Diagnostic Approach

7.7. Differential diagnosis

7.8. Treatment and Management

7.8.1. General Management

7.8.2. Surgical Management

7.8.3. Treatment Algorithm

8. Epidemiology and Patient Population

8.1. Key Findings

8.2. Methodology

8.3. Assumptions and Rationale: 7MM

8.4. Total Prevalent Cases of Neurotrophic keratopathy (NK) in the 7MM

8.5. Total Diagnosed Prevalent Cases of Neurotrophic keratopathy (NK) in the 7MM

8.6. The United States

8.6.1. Total Prevalent Cases of Neurotrophic keratopathy in the United States

8.6.2. Total Diagnosed Prevalent Cases of Neurotrophic keratopathy in the United States

8.6.3. Gender-specific Diagnosed Prevalent Cases of Neurotrophic keratopathy in the United States

8.6.4. Stage-specific Diagnosed Prevalent Cases of NK in the United States

8.7. EU5

8.7.1. Total Prevalent Cases of Neurotrophic keratopathy in EU-5

8.7.2. Total Diagnosed Prevalent Cases of Neurotrophic keratopathy in EU-5

8.7.3. Gender-specific Diagnosed Prevalent Cases of Neurotrophic keratopathy in EU-5

8.7.4. Stage-specific Diagnosed Prevalent Cases of Neurotrophic keratopathy in EU5

8.8. Japan

8.8.1. Total Prevalent Cases of Neurotrophic keratopathy in Japan

8.8.2. Total Diagnosed Prevalence of Neurotrophic keratopathy in Japan

8.8.3. Gender-specific Diagnosed Prevalent Cases of Neurotrophic keratopathy in Japan

8.8.4. Stage-specific Diagnosed Prevalent Cases of NK in Japan

9. Appendix

9.1. Report Methodology

9.2. Bibliography

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

List of Tables

Table 1: Key Events

Table 2: Causes and Locations of Neurotrophic Keratopathy

Table 3: Aetiopathogenesis of Neurotrophic Keratitis

Table 4: Total Prevalent Cases of  NK in the 7MM (2018–2030)

Table 5: Diagnosed Prevalent Cases of NK in the 7MM (2018–2030)

Table 6: Total Prevalent Cases of NK in the United States (2018–2030)

Table 7: Total Diagnosed Prevalent Cases of NK in the United States (2018–2030)

Table 8: Gender-specific Diagnosed Prevalent Cases of NK in the United States (2018–2030)

Table 9: Stage-specific Diagnosed Prevalent Cases of NK in the United States (2018–2030)

Table 10: Total Prevalent Cases of NK in EU-5 (2018–2030)

Table 11: Total Diagnosed Prevalent Cases of NK in EU-5 (2018–2030)

Table 12: Gender-specific Diagnosed Prevalent Cases of NK in EU-5 (2018–2030)

Table 13: Stage-specific Diagnosed Prevalent Cases of NK in EU-5 (2018–2030)

Table 14: Total Prevalent Cases of NK in Japan (2018–2030)

Table 15: Total Diagnosed Prevalent Cases of NK in Japan (2018–2030)

Table 16: Gender-specific Diagnosed Prevalent Cases of Neurotrophic keratopathy in Japan (2018–2030)

Table 17: Stage-specific Diagnosed Prevalent Cases of NK in Japan (2018–2030)

List of Figures

Figure 1: Symptoms of Neurotrophic keratopathy

Figure 2: Stage I Neurotrophic Keratitis - Cloudy and Irregular Corneal Epithelium

Figure 3: Stage II Neurotrophic Keratitis – Large Epithelial Defect Characterized by Smooth Edges

Figure 4: Stage III Neurotrophic Keratitis – Deep Corneal Ulcer and Stromal Melting

Figure 5: Overview of stages of NK, their causes, and effects

Figure 6: Common causes of neurotrophic keratitis

Figure 7: Stepwise Approach for the Diagnosis of Neurotrophic Keratitis

Figure 8: Treatment Options for Neurotrophic Keratitis Patients

Figure 9: Treatment Algorithm for Neurotrophic Keratitis

Figure 10: Total Prevalent Cases of NK in the 7MM (2018–2030)

Figure 11: Diagnosed Prevalent Cases of NK in the 7MM (2018–2030)

Figure 12: Total Prevalent Cases of NK in the United States (2018–2030)

Figure 13: Total Diagnosed Prevalent Cases of NK in the United States (2018–2030)

Figure 14: Gender-specific Diagnosed Prevalent Cases of NK in the United States (2018–2030)

Figure 15: Stage-specific Diagnosed Prevalent Cases of NK in the United States (2018–2030)

Figure 16: Total Prevalent Cases of NK in EU-5 (2018–2030)

Figure 17: Total Diagnosed Prevalent Cases of NK in EU-5 (2018–2030)

Figure 18: Gender-specific Diagnosed Prevalent Cases of NK in EU-5 (2018–2030)

Figure 19: Stage-specific diagnosed Prevalent Cases of NK in EU5 (2018–2030)

Figure 20: Total Prevalent Cases of NK in Japan (2018–2030)

Figure 21: Total Diagnosed Prevalent Cases of NK in Japan (2018–2030)

Figure 22: Gender-specific Diagnosed Prevalent Cases of NK in Japan (2018–2030)

Figure 23: Stage-specific Diagnosed Prevalent Cases of NK in Japan (2018–2030)

 

Forward to Friend

Need A Quote